Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Group A Streptococcus pleuropneumonia associated with toxic shock syndrome in a 64-year-old woman.

Imamdad P, Miailhes P, Bosch A, Ferry T.

BMJ Case Rep. 2019 May 8;12(5). pii: e228369. doi: 10.1136/bcr-2018-228369. No abstract available.

PMID:
31068344
2.

Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.

Chalouni M, Sogni P, Miailhes P, Lacombe K, Poizot-Martin I, Chas J, Vittecoq D, Neau D, Aumaitre H, Alric L, Piroth L, Bouchaud O, Katlama C, Morlat P, Lascoux-Combe C, Gervais A, Naqvi A, Rosenthal E, Garipuy D, Barange K, Esterle L, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

Eur J Gastroenterol Hepatol. 2019 Apr 25. doi: 10.1097/MEG.0000000000001408. [Epub ahead of print]

PMID:
31033848
3.

Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis.

Parant F, Miailhes P, Brunel F, Gagnieu MC.

Ther Drug Monit. 2019 Aug;41(4):444-451. doi: 10.1097/FTD.0000000000000618.

PMID:
30817698
4.

Patterns of HCV transmission in HIV-infected and HIV-negative men having sex with men.

Ramière C, Charre C, Miailhes P, Bailly F, Radenne S, Uhres AC, Brochier C, Godinot M, Chiarello P, Pradat P, Cotte L; Lyon Acute Hepatitis Study Group.

Clin Infect Dis. 2019 Feb 27. pii: ciz160. doi: 10.1093/cid/ciz160. [Epub ahead of print]

PMID:
30810158
5.

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.

Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin MA, Poizot-Martin I, Simon A, Rosenthal E, Lacombe K, Pialoux G, Bouchaud O, Gervais-Hasenknoff A, Goujard C, Piroth L, Zucman D, Dominguez S, Raffi F, Alric L, Bani-Sadr F, Lascoux-Combe C, Garipuy D, Miailhes P, Vittecoq D, Duvivier C, Aumaître H, Neau D, Morlat P, Dabis F, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

PLoS One. 2019 Jan 25;14(1):e0211286. doi: 10.1371/journal.pone.0211286. eCollection 2019.

6.

A practical approach to tuberculosis diagnosis and treatment in liver transplant recipients in a low-prevalence area.

Bosch A, Valour F, Dumitrescu O, Dumortier J, Radenne S, Pages-Ecochard M, Chidiac C, Ferry T, Perpoint T, Miailhes P, Conrad A, Goutelle S, Ader F; Lyon TB study Group.

Med Mal Infect. 2019 Jun;49(4):231-240. doi: 10.1016/j.medmal.2018.11.013. Epub 2018 Dec 24. Review.

PMID:
30591271
7.

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - a case report.

Alcazer V, Miailhes P, Ramière C, Charre C, Cotte L.

BMC Infect Dis. 2018 Dec 19;18(1):682. doi: 10.1186/s12879-018-3597-4.

8.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.

Billa O, Chalouni M, Salmon D, Poizot-Martin I, Gilbert C, Katlama C, Neau D, Chas J, Morlat P, Lacombe K, Naqvi A, Barange K, Gervais A, Bouchaud O, Rosenthal E, Lascoux-Combe C, Garipuy D, Alric L, Dominguez S, Vittecoq D, Goujard C, Duvivier C, Aumaitre H, Miailhes P, Zucman D, Simon A, Lazaro E, Raffi F, Esterle L, Wittkop L, Bani-Sadr F; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Dec 18;13(12):e0208657. doi: 10.1371/journal.pone.0208657. eCollection 2018.

9.

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.

Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L; ANRS CO13 Hepavih study Group.

World J Hepatol. 2018 Nov 27;10(11):856-866. doi: 10.4254/wjh.v10.i11.856.

10.

Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection.

Malagnino V, Bottero J, Miailhes P, Lascoux-Combe C, Girard PM, Zoulim F, Lacombe K, Boyd A.

J Med Virol. 2019 Apr;91(4):630-641. doi: 10.1002/jmv.25360. Epub 2018 Dec 3.

PMID:
30431661
11.

Severe tubulointerstitial nephritis: tracking tuberculosis even in the absence of renal granuloma.

Delafosse M, Teuma C, Miailhes P, Nouvier M, Rabeyrin M, Fouque D.

Clin Kidney J. 2018 Oct;11(5):667-669. doi: 10.1093/ckj/sfx157. Epub 2018 Jan 23.

12.

Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.

Miailhes P, Hartig-Lavie K, Virlogeux V, Pradat P, Diakite M, Uhres AC, Zoulim F, Sarda MN.

Clin Microbiol Infect. 2018 Nov;24(11):1215.e1-1215.e4. doi: 10.1016/j.cmi.2018.05.019. Epub 2018 Jun 2.

PMID:
29870852
13.

Dolutegravir-Related Neurological Adverse Events: A Case Report of Successful Management with Therapeutic Drug Monitoring.

Parant F, Miailhes P, Brunel F, Gagnieu MC.

Curr Drug Saf. 2018;13(1):69-71. doi: 10.2174/1574886313666180116124046.

PMID:
29345598
14.

Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men.

Charre C, Cotte L, Kramer R, Miailhes P, Godinot M, Koffi J, Scholtès C, Ramière C.

PLoS One. 2018 Jan 2;13(1):e0190340. doi: 10.1371/journal.pone.0190340. eCollection 2018.

15.

Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for screening patients with imported malaria in a non-endemic setting.

Ponce C, Kaczorowski F, Perpoint T, Miailhes P, Sigal A, Javouhey E, Gillet Y, Jacquin L, Douplat M, Tazarourte K, Potinet V, Simon B, Lavoignat A, Bonnot G, Sow F, Bienvenu AL, Picot S.

Parasite. 2017;24:53. doi: 10.1051/parasite/2017054. Epub 2017 Dec 18.

16.

Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients.

Boyd A, Lacombe K, Lavocat F, Miailhes P, Lascoux-Combe C, Girard PM, Zoulim F.

Antiviral Res. 2018 Jan;149:174-178. doi: 10.1016/j.antiviral.2017.11.014. Epub 2017 Nov 21.

PMID:
29169914
17.

Gender, Alcohol Use, and Fibrosis in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Individuals.

Yaya I, Costa M, Marcellin F, Miailhes P, Wittkop L, Salmon-Ceron D, Carrieri MP; Agence Nationale de Recherches sur le Sida et les Hépatites virales B et C (ANRS) CO13 HEPAVIH (hepatitis + VIH [= HIV in French]) Study Group.

Clin Infect Dis. 2018 Mar 5;66(6):983-984. doi: 10.1093/cid/cix927. No abstract available.

PMID:
29088334
18.

Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?

Piroth L, Launay O, Miailhes P, Carrat F, Rey D.

Clin Infect Dis. 2018 Jan 6;66(2):317-318. doi: 10.1093/cid/cix822. No abstract available.

PMID:
29020394
19.

Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.

Boyd A, Canini L, Gozlan J, Lascoux-Combe C, Miailhes P, Fonquernie L, Girard PM, Lacombe K.

J Clin Virol. 2017 Oct;95:55-60. doi: 10.1016/j.jcv.2017.08.008. Epub 2017 Aug 25.

PMID:
28869890
20.

Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

Boyd A, Bottero J, Miailhes P, Lascoux-Combe C, Rougier H, Girard PM, Serfaty L, Lacombe K.

J Int AIDS Soc. 2017 Feb 28;20(1):21426. doi: 10.7448/IAS.20.1.21426.

21.

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.

Lacombe K, Fontaine H, Dhiver C, Metivier S, Rosenthal E, Antonini T, Valantin MA, Miailhes P, Harent S, Batisse D, Pageaux GP, Chas J, Aumaitre H, Dominguez S, Allegre T, Lafeuillade A, Billaud E, De Truchis P, Perre P, Leroy V, De Ledinghen V, Sogni P, Dabis F, Zhao Y, Filipovics A, Fedchuk L, Akremi R, Bennai Y, Salmon Ceron D.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):97-107. doi: 10.1097/QAI.0000000000001342.

22.

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.

Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, Chas J, Poizot-Martin I, Gervais A, Dominguez S, Neau D, Zucman D, Billaud E, Morlat P, Aumaitre H, Lascoux-Combe C, Simon A, Bouchaud O, Teicher E, Bani-Sadr F, Alric L, Vittecoq D, Boué F, Duvivier C, Valantin MA, Esterle L, Dabis F, Sogni P, Salmon D; ANRS CO13 HEPAVIH study group.

J Hepatol. 2017 Jul;67(1):23-31. doi: 10.1016/j.jhep.2017.02.012. Epub 2017 Feb 22.

PMID:
28235612
23.

Autoimmune diseases and HIV infection: A cross-sectional study.

Virot E, Duclos A, Adelaide L, Miailhes P, Hot A, Ferry T, Seve P.

Medicine (Baltimore). 2017 Jan;96(4):e5769. doi: 10.1097/MD.0000000000005769.

24.

Potential effect of lamivudine-induced S gene mutations on liver-related pathogenesis in hepatitis D virus infection.

Boyd A, Miailhes P, Lacombe K, Zoulim F.

Hepatology. 2017 Apr;65(4):1424-1426. doi: 10.1002/hep.29062. Epub 2017 Mar 6. No abstract available.

PMID:
28103643
25.

Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.

Boyd A, Miailhes P, Lascoux-Combe C, Rougier H, Girard PM, Plaisier E, Lacombe K.

Antivir Ther. 2017;22(1):31-42. doi: 10.3851/IMP3076. Epub 2016 Aug 24.

PMID:
27553871
26.

Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.

Boyd A, Piroth L, Maylin S, Maynard-Muet M, Lebossé F, Bouix C, Lascoux-Combe C, Mahjoub N, Girard PM, Delaugerre C, Carrat F, Lacombe K, Miailhes P.

J Viral Hepat. 2016 Dec;23(12):1017-1026. doi: 10.1111/jvh.12581. Epub 2016 Aug 3.

PMID:
27486094
27.

All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.

Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miailhes P, Gervais A, Esterle L, Chas J, Poizot-Martin I, Dominguez S, Simon A, Morlat P, Neau D, Zucman D, Bouchaud O, Lascoux-Combe C, Bani-Sadr F, Alric L, Goujard C, Vittecoq D, Billaud E, Aumaître H, Boué F, Valantin MA, Dabis F, Salmon D, Wittkop L.

Clin Infect Dis. 2016 Sep 15;63(6):763-770. doi: 10.1093/cid/ciw379. Epub 2016 Jun 17.

PMID:
27317796
28.

Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.

Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, Delaugerre C, Girard PM, Zoulim F.

J Hepatol. 2016 Oct;65(4):683-691. doi: 10.1016/j.jhep.2016.05.014. Epub 2016 May 19.

PMID:
27210429
29.

Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).

Marcellin F, Protopopescu C, Poizot-Martin I, Miailhes P, Esterle L, Wittkop L, Spire B, Bocquier A, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group.

Eur J Gastroenterol Hepatol. 2016 Sep;28(9):1003-7. doi: 10.1097/MEG.0000000000000664.

PMID:
27177169
30.

Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.

Piroth L, Launay O, Michel ML, Bourredjem A, Miailhes P, Ajana F, Chirouze C, Zucman D, Wendling MJ, Nazzal D, Carrat F, Rey D, Binquet C; ANRS HB EP03 CISOVAC Study Group.

J Infect Dis. 2016 Jun 1;213(11):1735-42. doi: 10.1093/infdis/jiw011. Epub 2016 Jan 14.

PMID:
26768256
31.

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.

Morizot G, Jouffroy R, Faye A, Chabert P, Belhouari K, Calin R, Charlier C, Miailhes P, Siriez JY, Mouri O, Yera H, Gilquin J, Tubiana R, Lanternier F, Mamzer MF, Legendre C, Peyramond D, Caumes E, Lortholary O, Buffet P.

PLoS Negl Trop Dis. 2016 Jan 6;10(1):e0004304. doi: 10.1371/journal.pntd.0004304. eCollection 2016 Jan.

32.

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Grard S, Catho G, Valour F, Bouaziz A, Perpoint T, Braun E, Biron F, Miailhes P, Ferry T, Chidiac C, Souquet PJ, Couraud S, Lina G, Goutelle S, Veziris N, Dumitrescu O, Ader F.

Open Forum Infect Dis. 2015 Dec 22;2(4):ofv175. doi: 10.1093/ofid/ofv175. eCollection 2015 Dec.

33.

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy.

Pradat P, Virlogeux V, Maynard M, Leclercq M, Hatu G, Amiri M, Lebosse F, Miailhes P, Zoulim F, Gagnieu MC, Bailly F.

Hepat Mon. 2015 Sep 1;15(9):e28879. doi: 10.5812/hepatmon.28879. eCollection 2015 Sep.

34.

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.

Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, Billaud E, Molina JM, Launay O, Carrat F; ANRS HB04 B-BOOST study group.

Lancet Infect Dis. 2015 Nov;15(11):1283-91. doi: 10.1016/S1473-3099(15)00220-0. Epub 2015 Aug 6.

PMID:
26257021
35.

Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.

Boyd A, Gozlan J, Miailhes P, Lascoux-Combe C, Cam MS, Rougier H, Zoulim F, Girard PM, Lacombe K.

AIDS. 2015 Sep 24;29(15):1963-73. doi: 10.1097/QAD.0000000000000795.

PMID:
26153669
36.

Increased Regulatory T-Cell Percentage Contributes to Poor CD4(+) Lymphocytes Recovery: A 2-Year Prospective Study After Introduction of Antiretroviral Therapy.

Saison J, Maucort Boulch D, Chidiac C, Demaret J, Malcus C, Cotte L, Poitevin-Later F, Miailhes P, Venet F, Trabaud MA, Monneret G, Ferry T.

Open Forum Infect Dis. 2015 May 1;2(2):ofv063. doi: 10.1093/ofid/ofv063. eCollection 2015 Apr.

37.

Trends of the HIV/AIDS epidemic in Lyon University Hospitals from 1985 to 2011: continuous decrease since the introduction of HAART.

Febvey O, Bénet T, Baratin D, Miailhes P, Boibieux A, Brunel-Dalmas F, Makhloufi D, Ferry T, Vanhems P.

Int J Infect Dis. 2015 May;34:51-2. doi: 10.1016/j.ijid.2015.02.019. Epub 2015 Feb 26. No abstract available.

38.

Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy.

Seng R, Goujard C, Krastinova E, Miailhes P, Orr S, Molina JM, Saada M, Piroth L, Rouzioux C, Meyer L; ANRS PRIMO Cohort.

AIDS. 2015 Mar 13;29(5):595-607. doi: 10.1097/QAD.0000000000000571.

PMID:
25715104
39.

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group.

Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18.

PMID:
25701561
40.

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.

Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, Sogni P, Fontaine H, Rosenthal E, Winnock M, Loko MA, Wittkop L, Dabis F, Salmon D; ESCMID European Study Group on Viral Hepatitis.

Liver Int. 2015 Sep;35(9):2090-9. doi: 10.1111/liv.12799. Epub 2015 Feb 23.

PMID:
25650873
41.

Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.

Piroth L, Pol S, Miailhes P, Lacombe K, Lopes A, Fillion A, Loustaud-Ratti V, Borsa-Lebas F, Salmon D, Rosenthal E, Carrat F, Cacoub P; GERMIVIC Study Group.

Liver Int. 2015 Aug;35(8):1950-8. doi: 10.1111/liv.12777. Epub 2015 Jan 22.

PMID:
25559645
42.

Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.

Barau C, Braun J, Vincent C, Haim-Boukobza S, Molina JM, Miailhes P, Fournier I, Aboulker JP, Vittecoq D, Duclos-Vallée JC, Taburet AM, Teicher E; Agence Nationale de Recherche sur le Sida et les hépatites (ANRS) 148 Study Group.

Clin Infect Dis. 2014 Oct 15;59(8):1177-84. doi: 10.1093/cid/ciu515. Epub 2014 Jul 3.

PMID:
24992955
43.

Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.

Miailhes P, Maynard-Muet M, Lebossé F, Carrat F, Bouix C, Lascoux-Combe C, Sogni P, Rey D, Barthe Y, Pol S, Cacoub P, Zoulim F, Piroth L.

J Hepatol. 2014 Oct;61(4):761-9. doi: 10.1016/j.jhep.2014.05.030. Epub 2014 Jun 2.

PMID:
24882048
44.

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.

Hatu G, Bailly F, Pourcelot E, Pradat P, Miailhes P, Maynard M, Parant F, Chiarello P, Livrozet JM, Zoulim F, Gagnieu MC.

BMC Infect Dis. 2014 Mar 20;14:150. doi: 10.1186/1471-2334-14-150.

45.

Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients.

Boyd A, Miailhes P, Brichler S, Scholtès C, Maylin S, Delaugerre C, Chevallier-Queyron P, Gordien E, Girard PM, Lacombe K.

AIDS Res Hum Retroviruses. 2013 Dec;29(12):1535-40. doi: 10.1089/AID.2013.0008. Epub 2013 Sep 24.

46.

Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.

Pradat P, Le Pogam MA, Okon JB, Trolliet P, Miailhes P, Brochier C, Maynard M, Bailly F, Zoulim F, Cotte L.

J Viral Hepat. 2013 Sep;20(9):650-7. doi: 10.1111/jvh.12088. Epub 2013 Mar 5.

PMID:
23910650
47.

High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients.

Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Miailhes P, Lascoux-Combe C, Vernet G, Girard PM, Zoulim F.

Hepatology. 2013 Sep;58(3):912-22. doi: 10.1002/hep.26374. Epub 2013 Jun 25.

PMID:
23468093
48.

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.

Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E.

Genome Biol. 2013 Jan 15;13(3):2993. doi: 10.1186/gb-2012-13-3-1234.

49.

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.

Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E.

BMC Res Notes. 2012 Jul 9;5:180. doi: 10.1186/1756-0500-5-180.

50.

Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.

Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, Lassel L, Delaugerre C, Girard PM, Zoulim F, Lacombe K.

AIDS. 2012 May 15;26(8):939-49. doi: 10.1097/QAD.0b013e328352224d.

PMID:
22333748

Supplemental Content

Loading ...
Support Center